semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-70.0,  Atherosclerosis Sign written consent Age: 20-70 y BMI: 18.5 kg/m2 Healthy men and women (with no known diseases)  Current or previously cardiovascular disease, high blood pressure Diabetes Mellitus or other severe chronic disease, including severe allergies Use of dietary supplements and blood donations prior to, and during the study Known or suspected abuse of alcohol, drugs or medication Pregnant or are planning pregnancy during the study period Extreme physical activity level (more than 10 hours tough physical activity pr. week) Participation in other research studies Inability, physically or mentally, to comply with the procedures required by the study protocol, as evaluated by the study staff
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-80.0,  Dyslipidemia in Patients With Diabetes Mellitus patient should have all of the 3 1. Patient with diabetes mellitus, defined by at least 1 of the following: Fasting glucose > 125 mg/dL confirmed on 2 occasions HbA1C > 6.5% Patients receiving any glucose lowering agent (oral or subcutaneous) 2. Lipid profile should have ALL of the following characteristics: Triglycerides >150 mg/dL HDL <45 mg/dL LDL < 190 mg/dL 3. Lp(a) level < 30 mg/dL  Patients with known coronary artery disease defined by at least one of the following Prior myocardial infarction Prior PCI Prior CABG Known coronary stenosis > 50% on coronary angiography A non invasive study revealing myocardial ischemia (such as a stress test, a nuclear perfusion study or a stress echo) 2. Poor diabetic control defined by an HbA1c > 8.5% in the preceding 3 months 3. Patients with known diabetic retinopathy, nephropathy or neuropathy 4. Patients with a creatinin clearance < 75 ml/min as calculated by the Cockcroft-Gault equation 5. Patients who have received any lipid lowering therapy within 6 weeks prior to (statin, fibrates, ezetimibe, niacin, resin binding agent) 6. Patients with underlying malignancy or infection or inflammatory disease 7. Patients with SGPT or SGOT or CK > 2.5 times upper reference value 8. Patients allergic to statins or who experienced prior significant side effects with statins such as elevation of liver enzymes or CK > 2.5 upper reference value 9. Patients older than 80 10. Females who are premenopausal 11. Patients unable to give informed consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Muscle; Fatigue, Heart Healthy men between 18 and 35 years old Giving their writing informed consent And affiliated to the French social security  To be a smoker To present any known pathology that forbids the realisation of any test, or that can alter the measurements: cardiovascular risk factors treated or not (diabetes, dyslipidaemia, arterial hypertension, obesity), cardiac arrhythmia, coronary disease, heart failure, cardiac pacemaker or defibrillator, valvular disease after surgery or not, kidneys failure with dialyse or not, kidney pulmonary cardiac or liver transplantation, chronic bronchopneumopathy, asthma, etc To take any medication that could alter autonomic nervous system or cardiovascular adaptation to maximal exercise (anti-arrhythmia, anti-hypertensive, anti-inflammatory,…) Drinking exciting drinks (coffee or tee for example) in the 12h before the tests To be under legal protection (trusteeship, guardianship) or to be deprived of liberty
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 1 Blood Glucose Type 1 diabetes 2. Adult patients, age 18 or older and <75 years. 3. Written Informed Consent  Pregnancy 2. Patients with severe cognitive dysfunction or other disease which makes CGM use difficult. 3. Patients requiring continuous use of paracetamol. Paracetamol must not have been used the week before the study and shall not be used during the duration because it disturbs the interpretation of blood glucose levels estimated by the DexCom4G. However, other pain killers can be used throughout the study period. 4. Current CGM use 5. History of allergic reaction to any of the CGMS materials or adhesives in contact with the skin. 6. History of allergic reaction to chlorhexidine or alcohol anti-septic solution. 7. Abnormal skin at the anticipated glucose sensor attachment sites (excessive hair, burn, inflammation, infection, rash, and/or tattoo)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hyperglycemia critical care patients with blood glucose concentration >180mg/dl  insulin dependent diabetes
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-67.0,  Diabetes Diabetic Mellitus Type 2 medically controlled at Diabetes Center for at least six months BMI over 25 age between 20 and 67  Diagnosed with cancer within past five years HIV positive Active TB patients CV events in past six months serum cretinine over 2.0 mg/dl C-peptide bellow 1.0 ng/ml in past three months Diabetic retinopathy; vision bellow 0.1 Cushing's syndrome History of organ transplant History of bariatric surgery
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COPD Heart Failure Respiratory Failure Heart failure patients: age > 18 years who were in New York Heart Association class II-IV at time of discharge diagnosed by ESC guidelines Respiratory patients: age > 18 years with diagnosis of COPD or respiratory insufficiency due to chronic respiratory disorder diagnosed by Consultant Respiratory Physician (eg. bronchiectasis, chest wall disease, neuromuscular disorder) and arterial oxygen saturation value during most recent admission for exacerbation of 90% or below (or partial pressure of oxygen in arterial blood (PaO2) 8.0 kilopascal (kPa) or below) on air, or who fulfill for, and receive long term oxygen therapy  Age <18 years Cognitive impairment sufficient to interfere with use of telemonitoring system
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 30.0-80.0,  Diabetes Type 2 diabetes 2. HbA1c ≥ 7.5% 3. Age ≥ 30 4. low HDL-C (<40 mg/dl in men or <50 mg/dl in women) and having 1 or more risk factors: 1) Body mass index (BMI) ≥ 25 kg/m2 (overweight); 2) LDL-C level ≥ 130 mg/dl; 3) TG level ≥150 mg/dl; 4) Systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥140/90 mmHg or taking antihypertensive medication; 5) Current smoker; 6) Family history of CHD  Contraindication to rosuvastatin 2. Pregnant or breast feeding women 3. Reproductive-age women who refuse contraception 4. Type 1 diabetes, gestational diabetes, or diabetes with secondary cause 5. Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT > 3-fold the upper limit of normal) 6. Renal failure (Cr > 2.0) 7. Cancer within 5 years (except squamous cell cancer, cervical cancer, thyroid cancer with appropriate treatment) 8. Not appropriate for lipid lowering treatment 9. Medications which affect glycemic control 10. Diseases which affect efficacy and safety of statin 11. Other clinical trial within 30 days
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 8.0-21.0,  Arterial Stiffness in Youth With Type 1 Diabetes Type 1 diabetes based on clinical history Basal-bolus insulin regimen Duration of diabetes greater than 1 year Blood glucose 65-200 mg/dL fasting  Use of metformin or any other hypoglycemic agents besides insulin Use of anti-hypertensives Caffeine or smoking within the past 24 hours
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hyperlipidemia Must be treated with atorvastatin 40 mg/day for at least 30 days prior to screening Have an LDL-C >70 mg/deciliter(dL) or non-HDL-C >100 mg/dL Have screening triglycerides ≤400 mg/dL (≤4.5 millimoles/Liter) Individuals with ASCVD and/or individuals with type 1 or type 2 diabetes  Have a hemoglobin A1c (HbA1c) >9.5% New York Heart Association (NYHA) class III or IV congestive heart failure History of either a transient ischemic stroke or ischemic stroke <30 days History of acute coronary syndrome (ACS) <30 days
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Informed consent obtained before any study-related activities The following patients will be considered eligible for in the study: Patients with T1DM (Type 1 Diabetes Mellitus) or T2DM (Type 2 Diabetes Mellitus) treated with insulin for more than 12 months and patients at least 18 years of age at the time of the survey  Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation Illiterate patients and patients otherwise unable to complete a written survey Non-ambulatory patients Simultaneous participation in any other clinical study with an investigational product
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Obesity Metabolic Syndrome Pre-diabetes Type 2 Diabetes Cardiovascular Disease English-speaking adults aged 18+ years High-risk primary prevention: BMI 35+ and prediabetes (including hx of gestational diabetes) and/or metabolic syndrome Secondary prevention: BMI 30+ and type 2 diabetes and/or cardiovascular disease Able and willing to provide written informed consent  Medical determination that the study is inappropriate or unsafe for the patient Type 1 diabetes Safety concerns related to significant physical or mental health issues or life expectancy of less than 12 months Currently pregnant or lactating No regular telephone or broadband Internet access or otherwise unable to participate in the intervention
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 1.0-16.0,  Cardiomyopathy Age between 1-16 year(s) 2. LVEF <45% (echocardiography) 3. Duration of diagnosis more than 3 months 4. Resistance to Standard therapy more than 2 months 5. Informed consent  Congenital Heart Disease 2. Active infection less than one month 3. Dysrhythmia 4. Cardiogenic shock 5. Renal failure 6. Immune Deficiency (Documentation) 7. Terminal illness or malignancy(Documentation) 8. TORCH (Documentation) 9. Metabolic disorder (Documentation) 10. Neuromuscular disorder (Documentation) 11. Autoimmune disease (Documentation) 12. Developmental delay 13. Cytotoxic drugs 14. Previous bone marrow transplant 15. Contraindications to CMR such as metallic implants
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type 1 Diabetes Patients must reside in Liverpool or the surrounding areas Patients must be ages over 18 Patients must have Type 1 diabetes Patients must be using or pending the supply of an insulin pump  Patients must not live outside of Liverpool and the surrounding areas Patients must not be aged under 18
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type 1 Diabetes Patients must reside in Liverpool or the surrounding areas Patients must be ages over 18 Patients must have Type 1 diabetes Patients must be using or pending the supply of an insulin pump Patients who have been using either continuous subcutaneous insulin infusion or multiple daily injections for over a year  Patients must not live outside of Liverpool and the surrounding areas Patients must not be aged under 18